Ciltacabtagene Autoleucel

Summary

Ciltacabtagene Autoleucel (CHEMBL4802263) is an approved gene (ATC L01XL05); indicated across 1 condition including plasma cell myeloma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• ATC class: L01XL05
• Indications: 1 condition
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802263
Name	Ciltacabtagene Autoleucel
Type	Gene
Max phase	4
ATC	L01XL05

Also known as: Carvykti, Ciltacabtagene autoleucel, JNJ-68284528, JNJ-68284528(LCAR-B38M CAR-T cells), CILTACABTAGENE AUTOLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	2
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04133636	PHASE2	ACTIVE_NOT_RECRUITING	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT05767359	PHASE2	ACTIVE_NOT_RECRUITING	CAR- PRISM (PRecision Intervention Smoldering Myeloma)
NCT06940297	PHASE2	RECRUITING	Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
NCT03548207	PHASE1/PHASE2	COMPLETED	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
NCT06623630	PHASE1	RECRUITING	Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
NCT07093554	PHASE1	RECRUITING	Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
NCT06855121	Not specified	RECRUITING	The Norwegian Immunotherapy in Multiple Myeloma Study
NCT04452994	Not specified	NO_LONGER_AVAILABLE	Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).